Company* (Country; Symbol) Company* (Country; Symbol) Type/Product Area Terms/Details (Date) FIRST QUARTER Abgenix Inc. (ABGX) Genentech Inc. (NYSE:DNA) Genentech exercised its option to extend for three years a licensing agreement for antibody-generation technology Genentech purchased Abgenix stock and would pay milestone and royalty fees as products advance; the deal covering XenoMouse technology originally was signed in 1999 (3/14) Acadia Pharmaceuticals Inc. (ACAD) Sepracor Inc

2005 Biotech-Big Pharma Collaborations#: New Agreements Biotech Co.* (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date) FIRST QUARTER Addex Pharmaceuticals SA* (Switzerland) Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson) Collaboration to discover, develop and sell compounds that modulate allosterically GPCRs for treating various CNS diseases Addex gets an up-front fee and research funding for two years; it also could earn milestone and royalty

Biotech Co.* (Country; Symbol)# Pharma Co. (Country) Type/Product Area Terms/Details (Date) Ablynx NV* (Belgium) Procter & Gamble Co. They extended existing deal to include metabolic disease targets provided by P&G Ablynx is entitled to R&D funding, milestone payments and royalties on resulting products; it is using its Nanobody platform in the effort (4/10) Advanced Biotherapy Inc. (OTC BB:ADVB) Battelle Deal to develop monoclonal antibodies to treat humans and animals exposed to

Spectrum acquired LFA's sales and marketing rights in the U.S., Canada and Mexico, along with several other oncology drugs in various stages of development

Company* (Country; Symbol) Company* (Country; Symbol) Type/Product Area Terms/Details (Date) Aastrom Biosciences Inc. (ASTM) Orthovita Inc. (VITA) Collaboration to develop products for the orthopedics market They will use Orthovita's matrices technology with Aastrom's bone marrow-derived cells in the effort; terms were not disclosed (3/20) ACE BioSciences A/S* (Denmark) Nordic Vaccine A/S* (Denmark) Deal to develop fast-acting vaccines that provide better protection and can be

Commercial rights in the U.S., Canada and Japan fall within the scope of ImClone's commercial agreement with New York-based Bristol-Myers Squibb & Co., regarding Erbitux

The company gains exclusive sales and distribution rights in the U.S

Byetta is partnered with Indianapolis-based Eli Lilly and Co., which has co-promotion rights in the U.S

Elan is retaining all rights in the U.S

Elan is retaining all rights in the U.S. (See BioWorld Today, Feb. 10, 2006

Included most notably in the deal are the rights in the U.S., Canada and Mexico to the osteosarcoma therapy levofolinic acid (LFA), for which the NDA has been filed, though the FDA has asked questions about the portion of the filing that deals with chemistry, manufacturing and control

Barrett said XenoPort would like to maintain co-development and co-commercialization rights in the U.S., in which the company would seek to reach specialists through an internal sales force, while a partner would handle primary care sales and other such efforts abroad. (See BioWorld Today, Dec. 2, 2005.) Beyond RLS, XenoPort is planning XP13512’s development in neuropathic pain

Vertex holds development and commercial rights in the U.S

Cadence acquired rights in the U.S

January | February | March | April | May | June | July | August | September | October | November | December December - 2006 Company Company Type/Product Area Terms/Details AC Immune Ltd. (Switzerland) Genentech Inc. (NYSE:DNA) Deal to develop anti-beta-amyloid antibodies for treating Alzheimer's disease and other conditions AC Immune gets up-front and research funding; it could get more than $300M in milestones for Alzheimer's and additional indications, and would get royalties

and also has certain co-promotion rights in the U.S

and the Nordic region, as well as an exclusive option to license rights for the U.S., where the product is not yet approved

Durect is partnering the product with Endo Pharmaceuticals Inc., of Chadds Ford, Pa., which licensed development and commercialization rights in the U.S

Progenics retains co-promotion rights in the U.S., and is eligible for royalties on product sales outside the U.S